1. Home
  2. MIST vs VRCA Comparison

MIST vs VRCA Comparison

Compare MIST & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Milestone Pharmaceuticals Inc.

MIST

Milestone Pharmaceuticals Inc.

HOLD

Current Price

$0.36

Market Cap

95.3M

Sector

Health Care

ML Signal

HOLD

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

SELL

Current Price

$3.26

Market Cap

88.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MIST
VRCA
Founded
2003
2013
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.3M
88.0M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
MIST
VRCA
Price
$0.36
$3.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
5
Target Price
$4.14
★ $13.80
AVG Volume (30 Days)
★ 1.3M
51.0K
Earning Date
11-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $35,577,000.00
Revenue This Year
$210.30
N/A
Revenue Next Year
$251.88
$54.67
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 370.22
52 Week Low
$0.50
$3.08
52 Week High
$3.06
$9.82

Technical Indicators

Market Signals
Indicator
MIST
VRCA
Relative Strength Index (RSI) 24.59 43.75
Support Level N/A $3.19
Resistance Level $0.84 $5.94
Average True Range (ATR) 0.08 0.31
MACD -0.02 0.06
Stochastic Oscillator 0.00 26.55

Price Performance

Historical Comparison
MIST
VRCA

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Share on Social Networks: